NextFin News - India’s pharmaceutical industry is nearing a historic milestone as export revenues approached the $29 billion mark in the eleven months ending February 2026, demonstrating a robust 5.6% growth despite a landscape of tightening global regulations and persistent supply chain disruptions. Data from the Pharmaceuticals Export Promotion Council of India (Pharmexcil) indicates that total exports for the April-February period reached $28.29 billion, positioning the sector to potentially eclipse the record $30.47 billion achieved in the previous fiscal year.
The performance is particularly notable given the "global headwinds" cited by industry officials, ranging from pricing pressures in the United States to logistical hurdles in the Red Sea. According to R. Uday Bhaskar, Director General of Pharmexcil, the resilience of the sector is anchored in the increasing demand for generic medicines and India’s expanding footprint in emerging markets like Brazil and Africa. Bhaskar, who has long advocated for a shift from "volume to value" in Indian manufacturing, noted that the current trajectory reflects a structural strengthening of the supply chain rather than a temporary surge in demand.
While the headline figures suggest a sector in full bloom, the growth is not uniform across all geographies. The United States remains the largest destination for Indian drugs, accounting for roughly 30% of total exports, but manufacturers there face intensifying scrutiny from the U.S. Food and Drug Administration (FDA). Recent inspections have led to a rise in "Official Action Indicated" (OAI) statuses for several major Indian plants, a factor that some analysts warn could dampen the growth rate in the coming quarters. This regulatory friction serves as a critical counter-narrative to the optimism surrounding the $29 billion figure.
Beyond the U.S., the strategic pivot toward Latin America and Southeast Asia is yielding tangible results. Exports to Brazil, for instance, saw a significant double-digit increase in the current fiscal year as Indian firms successfully navigated local certification requirements. This diversification strategy is essential for mitigating the risks associated with over-reliance on any single market. However, the industry remains vulnerable to the volatility of raw material costs, particularly Active Pharmaceutical Ingredients (APIs), where dependence on external suppliers continues to be a strategic bottleneck despite government-led production-linked incentive (PLI) schemes.
The financial health of the sector also faces a test from the rising costs of compliance. As global standards for "Good Manufacturing Practices" (GMP) evolve, Indian mid-sized firms are being forced to choose between expensive facility upgrades or exiting the export market altogether. This consolidation trend may lead to a more resilient industry in the long run, but in the short term, it risks thinning the ranks of the very exporters that have driven India’s reputation as the "pharmacy of the world."
The final tally for the 2025-26 fiscal year will likely hinge on the performance of the biologics and specialty chemicals segments, which carry higher margins than traditional oral solids. While the $29 billion milestone is a testament to the industry's current momentum, the sustainability of this growth will depend on how effectively Indian manufacturers can transition into these more complex therapeutic areas while maintaining their competitive edge in the global generics market.
Explore more exclusive insights at nextfin.ai.
